Views of Wockhardt's Manufacturing Facilities As Indian Pharmaceuticals Breach Quality Control

Signage recording Wockhardt Ltd.'s effluent discharge from the company's manufacturing facility at in the Waluj industrial area sits behind a roadside tea stall in Aurangabad, India, on Monday, Sept. 16, 2013. Wockhardt currently controls about 26 percent of the U.S. market for metoprolol, a generic version of the heart pill sold by London-based AstraZeneca Plc under the brand name Toprol-XL, according to Needham & Co. Metoprolol alone makes up about 14 percent of the company's 56 billion rupees in annual revenue. Photographer: Dhiraj Singh/Bloomberg via Getty Images
Signage recording Wockhardt Ltd.'s effluent discharge from the company's manufacturing facility at in the Waluj industrial area sits behind a roadside tea stall in Aurangabad, India, on Monday, Sept. 16, 2013. Wockhardt currently controls about 26 percent of the U.S. market for metoprolol, a generic version of the heart pill sold by London-based AstraZeneca Plc under the brand name Toprol-XL, according to Needham & Co. Metoprolol alone makes up about 14 percent of the company's 56 billion rupees in annual revenue. Photographer: Dhiraj Singh/Bloomberg via Getty Images
Views of Wockhardt's Manufacturing Facilities As Indian Pharmaceuticals Breach Quality Control
COMPRAR UMA LICENÇA
Como posso utilizar esta imagem?
475,00 €
EUR

DETALHES

Restrições:
Contacte o representante local para todos os usos comerciais ou promocionais.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Crédito:
Bloomberg / Colaborador
Editorial #:
181964933
Coleção:
Bloomberg
Data da criação:
16 de setembro de 2013
Data do upload:
Tipo de licença:
Inf. sobre autorização:
Não tem autorização. Mais informações
Fonte:
Bloomberg
Nome do objeto:
INDIA WOCKHARDT